Answers are grounded in this paper and cite their sources.
Background: Hybrid closed-loop (HCL) therapy helps reaching efficacy and safety glucose targets (ESGT+) in persons with type 1 diabetes (PwT1D). We analyzed here the glycemia risk index (GRI) in PwT1D at HCL initiation (M 0 ) and at 12 months (M 12 ) and determined whether M 0 GRI value and/or M 0 GRI zone (A-B-C-D-E) could identify people reaching M 12 ESGT+. Methods: This was a retrospective study. Consecutive PwT1D who started HCL in a CIRDIA center were included after written consent. Glucose parameters were manually extracted from platforms at M 0 and M 12 . ESGT+ meant reaching time in range (TIR) > 70% and glucose management indicator < 7% and time below range (TBR) <70 < 4% and TBR <54 < 1%. Glycemia risk index was calculated and receiver-operating characteristic (ROC) analyses were performed to study the relation between M 0 GRI and M 12 ESGT+/M 12 ESGT–. Results: M 12 data were available for 128 PwT1D. M 0 GRI predicted M 12 ESGT mostly for low and high M 0 GRI values. An M 0 GRI < 41 had a 90% specificity, a 36% sensitivity, and a 74% positive predictive value for M 12 ESGT+. Sensitivity increased to 80% but specificity dropped to 56% for M 0 GRI < 61 and M 0 GRI ≥ 61 had a 78% negative predictive value. All PwT1D with M 0 GRI 0 to 20 (zone A) reached M 12 ESGT+. Then, the percentage of M 12 ESGT+ people dropped about 25% per M 0 GRI zone (A-B-C-D) and to 11% for zone E. Conclusions: M 0 GRI was significantly associated with M 12 ESGT status but mostly when in zones A-B or D-E. Hybrid closed-loop training should focus on PwT1D with M 0 GRI ≥ 41 (90% of M 12 ESGT– persons), but reaching M 12 ESGT+ is possible with M 0 GRI in zones C-D-E (64% of M 12 ESGT+ persons) and even D-E (20% of M 12 ESGT+ persons).
No takes yet. Share an insight, caveat, or question.
Picard et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: